

Nwora Lance Okeke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9315000/publications.pdf>

Version: 2024-02-01

45
papers

860
citations

687363

13
h-index

501196

28
g-index

48
all docs

48
docs citations

48
times ranked

1626
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Syphilis. JAMA - Journal of the American Medical Association, 2014, 312, 1905.	7.4	201
2	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 2021, 12, 2349.	12.8	194
3	Enhancing Linkage and Retention in HIV Care: a Review of Interventions for Highly Resourced and Resource-Poor Settings. Current HIV/AIDS Reports, 2014, 11, 376-392.	3.1	68
4	Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. Clinical Infectious Diseases, 2016, 63, 407-413.	5.8	49
5	An educational initiative in response to identified PrEP prescribing needs among PCPs in the Southern U.S.. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 650-655.	1.2	49
6	Hypertension Among HIV-infected Patients in Clinical Care, 1996â€“2013. Clinical Infectious Diseases, 2016, 63, 242-248.	5.8	39
7	Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. Journal of Cardiac Failure, 2018, 24, 496-503.	1.7	22
8	Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 475-482.	1.2	19
9	Use of a human-centered design approach to adapt a nurse-led cardiovascular disease prevention intervention in HIV clinics. Progress in Cardiovascular Diseases, 2020, 63, 92-100.	3.1	19
10	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2021, 8, ofab537.	0.9	19
11	â€œItâ€™s because I think too muchâ€“ Perspectives and experiences of adults with hypertension engaged in HIV care in northern Tanzania. PLoS ONE, 2020, 15, e0243059.	2.5	18
12	Rationale and design of a nurse-led intervention to extend the HIV treatment cascade for cardiovascular disease prevention trial (EXTRA-CVD). American Heart Journal, 2019, 216, 91-101.	2.7	17
13	Endogenous Candida endophthalmitis: Who is really at risk?. Journal of Infection, 2021, 82, 276-281.	3.3	15
14	Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naive Patient. Open Forum Infectious Diseases, 2018, 5, ofy294.	0.9	14
15	Metabolites predict cardiovascular disease events in persons living with HIV: a pilot caseâ€“control study. Metabolomics, 2018, 14, 1.	3.0	11
16	Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. American Journal of Cardiology, 2019, 124, 966-971.	1.6	11
17	Social Disadvantage, Politics, and Severe Acute Respiratory Syndrome Coronavirus 2 Trends: A County-level Analysis of United States Data. Clinical Infectious Diseases, 2021, 72, e604-e607.	5.8	11
18	Health Care Utilization Behaviors Predict Disengagement From HIV Care: A Latent Class Analysis. Open Forum Infectious Diseases, 2018, 5, ofy088.	0.9	8

#	ARTICLE	IF	CITATIONS
19	Role of raltegravir in the management of HIV-1 infection. HIV/AIDS - Research and Palliative Care, 2011, 3, 81.	0.8	6
20	The influence of healthcare financing on cardiovascular disease prevention in people living with HIV. BMC Public Health, 2020, 20, 1768.	2.9	6
21	Cardiovascular Disease Risk Management in Persons With HIV: Does Clinician Specialty Matter?. Open Forum Infectious Diseases, 2020, 7, ofaa361.	0.9	6
22	Understanding constraints on integrated care for people with HIV and multimorbid cardiovascular conditions: an application of the Theoretical Domains Framework. Implementation Science Communications, 2021, 2, 17.	2.2	6
23	Preexposure Prophylaxis Outcomes in an Urban Community in North Carolina: Discontinuation of Care and Sexually Transmitted Infections. Sexually Transmitted Diseases, 2021, 48, 183-188.	1.7	5
24	<p>Why Do People Living with HIV Adhere to Antiretroviral Therapy and Not Comorbid Cardiovascular Disease Medications? A Qualitative Inquiry</p>. Patient Preference and Adherence, 2020, Volume 14, 985-994.	1.8	4
25	Awareness and acceptability of HIV pre-exposure prophylaxis (PrEP) among students at two historically Black universities (HBCU): a cross-sectional survey. BMC Public Health, 2021, 21, 943.	2.9	4
26	Perspectives of HIV specialists and cardiologists on the specialty referral process for people living with HIV: a qualitative descriptive study. BMC Health Services Research, 2022, 22, 623.	2.2	4
27	Understanding Retention in Pre-Exposure Prophylaxis Care in the South: Insights from an Academic HIV Prevention Clinic. AIDS Research and Human Retroviruses, 2022, 38, 306-312.	1.1	3
28	Feasibility, Acceptability, and Preliminary Efficacy of a Gamified Mobile Health Contingency Management Intervention for PrEP Adherence Among Black MSM. AIDS and Behavior, 2022, 26, 3311-3324.	2.7	3
29	Fever and Rash in a Patient With Hepatitis. JAMA - Journal of the American Medical Association, 2015, 314, 400.	7.4	2
30	Partnerships between a University-Affiliated Clinic and Community Based Organizations to Reach Black Men who have Sex with Men for PrEP Care. Open Forum Infectious Diseases, 2017, 4, S438-S438.	0.9	2
31	Improving Care for Older Adults with HIV: Identifying Provider Preferences and Priorities. Journal of the American Geriatrics Society, 2020, 68, 891-892.	2.6	2
32	Perspectives of Chronic Disease Management Among Persons with HIV: A Qualitative Study. Patient Preference and Adherence, 2021, Volume 15, 49-55.	1.8	2
33	Progression of cardiac structure and function in people with human immunodeficiency virus. Echocardiography, 2022, 39, 268-277.	0.9	2
34	COVID-19 Trials: Who Participates and Who Benefits?. Southern Medical Journal, 2022, 115, 256-261.	0.7	2
35	Elevations of Short-Chain Dicarboxylacylcarnitine (SCDA) Levels Precede Major Cardiovascular Events in HIV-Infected Persons. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
36	Treatment of Late-Stage Syphilisâ€”Reply. JAMA - Journal of the American Medical Association, 2015, 313, 969.	7.4	0

#	ARTICLE	IF	CITATIONS
37	Healthcare Engagement among Persons with HIV: More Than Just Viral Load and Clinic Attendance. Open Forum Infectious Diseases, 2017, 4, S419-S419.	0.9	0
38	Title is missing!. , 2020, 15, e0243059.		0
39	Title is missing!. , 2020, 15, e0243059.		0
40	Title is missing!. , 2020, 15, e0243059.		0
41	Title is missing!. , 2020, 15, e0243059.		0
42	Title is missing!. , 2020, 15, e0243059.		0
43	Title is missing!. , 2020, 15, e0243059.		0
44	Title is missing!. , 2020, 15, e0243059.		0
45	Title is missing!. , 2020, 15, e0243059.		0